Načítá se...
Pharmacokinetics and safety of TCMCB07, a melanocortin‐4 antagonist peptide in dogs
The melanocortin‐4 receptor (MC4R) antagonistic peptide TCMCB07 was developed for the treatment of cachexia. The objectives of this study were to examine pharmacokinetics and safety of TCMCB07 administered subcutaneously to healthy dogs. Dogs were treated with high‐ (2.25 mg kg(−1)) (n = 5) and low‐...
Uloženo v:
| Vydáno v: | Pharmacol Res Perspect |
|---|---|
| Hlavní autoři: | , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8135083/ https://ncbi.nlm.nih.gov/pubmed/34014033 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/prp2.777 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|